Latest newsletter from our largest shareholder.
Starting to sing the praises for CZD.
http://www.merchantgroup.com.au/news/merchant-opportunities-fund-newsletter-april-2013.html
Interesting month in the markets, the trend continued from March and the broader index closed slightly higher.
The Merchant Opportunities Fund (MOF) had a positive month with the fund up 16.20%. Most (listed) companies in the portfolio made positive contributions to the performance of the fund with the greatest driver of performance being from Calzada (ASX: CZD).
As eluded to in previous newsletters, we were eagerly awaiting the results from the NovoSorb Human Clinical Trials and these proved to be nothing short of spectacular. We congratulate Laurent Fossaert (CEO PolyNovo) and Dr John Greenwood and their teams on these exciting developments. I haven’t seen too many charts like this lately, but am pleased to see one where we have a large amount of leverage
We expect to see Calzada continue to capitalise on this success over the coming months, in the lead up to further results of the BTM trials and progress updates from the 510K application in the US. Calzada has also been referenced in the mainstream media recently with continuing focus on the sporting community, for the use of Peptide AOD9604 by athletes in both the AFL and NRL codes. The investigations are currently centring around the AFL clubs; Essendon and Melbourne and whilst there is evidence the Peptide shows positive results in certain circumstances, the challenge remains for Metabolic to translate this into a tangible commercial transaction.
Add to My Watchlist
What is My Watchlist?